Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis-Reference-Cited by-同舟云学术

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis

Published:2023-12 Issue:12 Volume:29 Page:750-756
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Derigs Patrick^ORCID,Bethge Wolfgang A.,Krämer Isabelle,Holtick Udo,von Tresckow Bastian^ORCID,Ayuk Francis^ORCID,Penack Olaf,Vucinic Vladan^ORCID,von Bonin Malte,Baldus Claudia^ORCID,Mougiakakos Dimitrios,Wulf Gerald,Schnetzke Ulf,Stelljes Matthias^ORCID,Fante Matthias,Schroers Roland,Kroeger Nicolaus,Dreger Peter

Funder

Deutsches Krebsforschungszentrum

Dieter Morszeck Stiftung

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference23 articles.

1. Real-world evidence of axicabtagene ciloleucel for the treatment of large B-cell lymphoma in the United States;Jacobson;Transplant Cell Ther,2022

2. A national service for delivering CD19 CAR-T in large B-cell lymphoma: the UK real-world experience;Kuhnl;Br J Haematol,2022

3. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma;Kwon;Haematologica,2023

4. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma;Bachy;Nat Med,2022

5. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy;Chow;Am J Hematol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced‐intensity conditioning with fludarabine/busulfan versus fludarabine/low‐dose melphalan in patients with non‐Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation;British Journal of Haematology;2024-07-24

2. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study;The Lancet;2024-07

3. CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma;The Lancet;2024-07

4. Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients;Expert Opinion on Biological Therapy;2024-05-03

5. Long-term Survivors and Failures of CAR-T Therapy for Lymphoma: Is there a Role for Allogeneic Transplantation After the CAR-T Crash?;Transplantation and Cellular Therapy;2023-12